Integrium Funding: How Much Did They Raise & Key Investors

How Much Did Integrium Raise?
Funding & Key Investors

Integrium, a specialized clinical proof of concept organization, has successfully secured significant capital to bolster its operational capabilities. The firm, which has reached a total valuation milestone represented by $956K, recently finalized a major strategic investment totaling $606K. This infusion of liquidity underscores the company's pivotal role in supporting micro-cap and small-cap biotechs as they navigate the complex regulatory and clinical landscapes required to bring innovative therapies to market.

The trajectory of Integrium's financial growth is marked by a series of debt-based financing rounds, beginning with an initial capital injection in April 2020, followed by a subsequent expansion of its financial resources in March 2021. This consistent backing reflects investor confidence in the firm's specialized service model, which bridges the gap between early-stage research and commercial viability for innovator and generic drug developers alike.

What is Integrium?

Integrium

Business Services

Research & Development

Headquartered in Tustin, California, with a strategic presence in Cedar Knolls, New Jersey, Integrium operates as a full-service clinical research partner. Since its inception in 1998, the company has cultivated deep expertise across a diverse range of therapeutic areas, including Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. By providing essential clinical data and strategic guidance, Integrium enables privately held and publicly traded biotechs to optimize their development pipelines. The firm's secondary focus on complex regulatory categories, such as Schedule 2 drugs and Oncology, positions it as a high-value partner for organizations seeking to mitigate risk while accelerating the clinical proof of concept phase.

How much funding has Integrium raised?

Integrium has raised a total of $956K across 2 funding rounds:

2020

Debt

$350K

2021

Debt

$606K

Debt (2020): $350K with participation from PPP

Debt (2021): $606K led by PPP

Key Investors in Integrium

PPP

Public-Private Partnership

What's next for Integrium?

With the recent influx of capital, Integrium is well-positioned to scale its service offerings and deepen its therapeutic reach. The company's strategic roadmap likely involves enhancing its clinical trial infrastructure and expanding its footprint within the high-growth gene therapy and oncology sectors. As the biotech industry continues to face pressure to deliver data-driven results, Integrium's ability to provide comprehensive clinical support will be a critical differentiator. Future growth will likely focus on leveraging this recent financing to attract larger-scale innovator clients, thereby solidifying its market position as a premier clinical research organization capable of navigating the most challenging therapeutic development cycles.

See full Integrium company page

See More Financial Insights